# EDGAR Filing Document

**Accession Number:** 0001703057
**File Stem:** 0001703057-25-000018
**Filing Date:** 2025-9
**Character Count:** 7931
**Document Hash:** 237a1bcabe0283249459626af84c49f2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001703057-25-000018.hdr.sgml**: 20250910

**ACCESSION NUMBER**: 0001703057-25-000018

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250910

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250910

**DATE AS OF CHANGE**: 20250910

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AbCellera Biologics Inc.
- **CENTRAL INDEX KEY:** 0001703057
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39781
- **FILM NUMBER:** 251305231

**BUSINESS ADDRESS:**
- **STREET 1:** 150 W 4TH AVENUE
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V5Y 1G6
- **BUSINESS PHONE:** (604) 559-9005

**MAIL ADDRESS:**
- **STREET 1:** 150 W 4TH AVENUE
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V5Y 1G6

?xml version='1.0' encoding='ASCII'? abcl-20250910

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**__________________________________________**

**FORM 8-K**

**__________________________________________**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): September 10, 2025**

**__________________________________________**

**AbCellera Biologics Inc.**

**(Exact name of registrant as specified in its charter)**

**__________________________________________**

---

| | | |
|:---|:---|:---|
| **British Columbia** | **001-39781** | **Not Applicable** |
| **(State or other jurisdiction of incorporation)** | **(Commission File Number)** | **(IRS Employer Identification Number)** |

---

---

| | |
|:---|:---|
| **150 W 4th Avenue** <br>**Vancouver, BC** | **V5Y 1G6** |
| **(Address of registrant's principal executive office)** | **(Zip code)** |

---

**(604) 559-9005**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

**__________________________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| Common shares | ABCL | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 8.01&nbsp;&nbsp;&nbsp;&nbsp;Other Events**

On September 10, 2025, AbCellera Biologics Inc. (the "Company"), issued a press release announcing the appointment of Sarah Noonberg, M.D., Ph.D., as the Company's Chief Medical Officer. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | <u>[Press Release issued by AbCellera Biologics Inc. on](pressrelease-cmo.htm)[September](pressrelease-cmo.htm)[10](pressrelease-cmo.htm)[,](pressrelease-cmo.htm)[2025.](pressrelease-cmo.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded as Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: September 10, 2025 | **ABCELLERA BIOLOGICS INC.** | **ABCELLERA BIOLOGICS INC.** |
|  | By: | /s/ Carl L. G. Hansen |
|  |  | **Carl L. G. Hansen, Ph.D.** |
|  |  | **Chief Executive Officer and Director**<br>*(Principal Executive Officer)* |

---

## Exhibit 99.1

![](pressrelease-cmo001.jpg)

150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Appoints Dr. Sarah Noonberg as Chief Medical O�cer 2025-09-10 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical O�cer. Dr. Noonberg, a board-certi�ed physician-scientist, brings over two decades of industry experience leading development programs from discovery through to global regulatory approvals and commercialization across a diverse range of indications and therapeutic modalities, including oncology, neuroscience, rare diseases, gene therapy, and cell therapy. As Chief Medical O�cer, Dr. Noonberg, will leverage her clinical development background to advance AbCellera's pipeline of antibody-based therapeutics. "We are pleased to welcome Sarah as AbCellera's �rst Chief Medical O�cer," said Carl Hansen, PhD, founder and CEO of AbCellera. "With more than 20 years of experience in clinical development, Sarah brings deep expertise and proven operational and leadership strength that will be invaluable as we continue to build and advance our clinical pipeline." "I'm honored to join AbCellera at such an exciting time as it transitions to a clinical stage company," said Dr. Noonberg. "I look forward to working with the team to advance a growing portfolio of important therapies that have the potential to improve patient's lives." Dr. Noonberg was most recently the Chief Medical O�cer of Metagenomi, where she led the translation of its gene editing platform into a pipeline strategy and contributed to its ~$100M initial public offering. Prior to Metagenomi, Dr. Noonberg served as Chief Medical O�cer at multiple companies, including Maze Therapeutics, Nohla Therapeutics, and Prothena Biosciences; as Group Vice President and Head of Global Clinical Development at BioMarin; and as Senior Vice President at Medivation, where she contributed to the development of enzalutamide 1

------

![](pressrelease-cmo002.jpg)

(XTANDI™) for prostate cancer. Dr. Noonberg is currently a board member of Neurogene and a past board member of Marinus Pharmaceuticals and Protagonist Therapeutics. Dr. Noonberg received her M.D. from the University of California, San Francisco, her Ph.D. in Bioengineering from the University of California, Berkeley, and completed her internal medicine residency at the Johns Hopkins Hospital. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com. Inquiries Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116 Source: AbCellera Biologics Inc. 2

------